Salarius regains Nasdaq equity compliance; fully compliant ahead of Decoy merger

Decoy Therapeutics Inc.

Received Nasdaq letter on Oct 10, 2025 confirming compliance with minimum stockholders' equity requirement (Rule 5550(b)(1)).
Now fully compliant with all Nasdaq listing requirements, having also regained bid price compliance on Sept 9, 2025.
Subject to a Mandatory Panel Monitor for one year from Oct 10, 2025; noncompliance could lead to delisting without a cure period.
Planned merger with Decoy Therapeutics (announced Jan 13, 2025) remains on track; combined company to be named Decoy Therapeutics.
Post-merger pipeline includes pan-coronavirus antiviral IND filing within 12 months and data from MD Anderson seclidemstat study.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001615219-25-000145
form_type: 8-K
ticker: DCOY
cik: 0001615219
company_name: Decoy Therapeutics Inc.
filed_at: 2025-10-14T23:59:59+00:00
discovered_at: 2026-05-14T18:02:39.926357+00:00
generated_at: 2026-05-17T03:54:11.886988+00:00
sec_items: ["8.01", "9.01"]
event_type: regulatory
sentiment: positive
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001615219-25-000145
json_url: https://secwatch.observer/filing/0001615219-25-000145.json
markdown_url: https://secwatch.observer/filing/0001615219-25-000145.md
text_url: https://secwatch.observer/filing/0001615219-25-000145.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000145/0001615219-25-000145-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000145/flks-20251010.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001615219-25-000145

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.